Cargando…

Biologics: how far can they go in Crohn’s disease?

Crohn’s disease is a chronic gastrointestinal inflammatory disorder, characterized by episodes of relapsing and remitting flares. As the disease mechanism becomes better elucidated, there is a significant increase in the number of available biologic therapies. This article summarizes and synthesizes...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunleavy, Katie A, Pardi, Darrell S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522383/
https://www.ncbi.nlm.nih.gov/pubmed/36196255
http://dx.doi.org/10.1093/gastro/goac049
_version_ 1784800054391865344
author Dunleavy, Katie A
Pardi, Darrell S
author_facet Dunleavy, Katie A
Pardi, Darrell S
author_sort Dunleavy, Katie A
collection PubMed
description Crohn’s disease is a chronic gastrointestinal inflammatory disorder, characterized by episodes of relapsing and remitting flares. As the disease mechanism becomes better elucidated, there is a significant increase in the number of available biologic therapies. This article summarizes and synthesizes current Food and Drug Administration-approved biological therapy for Crohn’s disease and examines the positioning of medical therapy as emerging biologics break onto the market.
format Online
Article
Text
id pubmed-9522383
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95223832022-10-03 Biologics: how far can they go in Crohn’s disease? Dunleavy, Katie A Pardi, Darrell S Gastroenterol Rep (Oxf) Review Article Crohn’s disease is a chronic gastrointestinal inflammatory disorder, characterized by episodes of relapsing and remitting flares. As the disease mechanism becomes better elucidated, there is a significant increase in the number of available biologic therapies. This article summarizes and synthesizes current Food and Drug Administration-approved biological therapy for Crohn’s disease and examines the positioning of medical therapy as emerging biologics break onto the market. Oxford University Press 2022-09-29 /pmc/articles/PMC9522383/ /pubmed/36196255 http://dx.doi.org/10.1093/gastro/goac049 Text en © The Author(s) 2022. Published by Oxford University Press and Sixth Affiliated Hospital of Sun Yat-sen University https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Dunleavy, Katie A
Pardi, Darrell S
Biologics: how far can they go in Crohn’s disease?
title Biologics: how far can they go in Crohn’s disease?
title_full Biologics: how far can they go in Crohn’s disease?
title_fullStr Biologics: how far can they go in Crohn’s disease?
title_full_unstemmed Biologics: how far can they go in Crohn’s disease?
title_short Biologics: how far can they go in Crohn’s disease?
title_sort biologics: how far can they go in crohn’s disease?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522383/
https://www.ncbi.nlm.nih.gov/pubmed/36196255
http://dx.doi.org/10.1093/gastro/goac049
work_keys_str_mv AT dunleavykatiea biologicshowfarcantheygoincrohnsdisease
AT pardidarrells biologicshowfarcantheygoincrohnsdisease